Animal Antibiotics and Antimicrobials Market

Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026

Report Code: PH 2458 Mar, 2021, by marketsandmarkets.com

[255 Pages Report] The global animal antimicrobials and antibiotics market is projected to reach USD 5.6 billion by 2026 from USD 4.7 billion in 2021, at a CAGR of 3.6% from 2021 to 2026. Market growth can largely be attributed to the rising demand for animal-derived food products, increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases. Rising animal healthcare spending and the growing demand for pet insurance are further expected to drive the growth of this market. The untapped emerging markets such as China, India, and Brazil and growth in the overall companion animal population are also expected to offer significant growth opportunities to market players in the coming years

However, the limited number of new antibiotics, growing resistance to antimicrobials and antibiotics, and increasing good husbandry and hygiene practices are expected to hinder the growth of this market to a certain extent.

In this report, animal antimicrobials and antibiotics market, by the type of product, mode of delivery, animal type, and region

Animal Antibiotics and Antimicrobials Market

To know about the assumptions considered for the study, download the pdf brochure

COVID-19 Impact on the Animal Antimicrobials and Antibiotics Market

To assess the impact of COVID-19 and provide market forecasts, scenario-based approaches are considered.

  • In the optimistic/normal scenario, the pandemic is expected to have a temporary and minimal impact on the animal antimicrobials and antibiotics market or its growth during the forecast period. Hence, the market size in the entire report is considered for an optimistic scenario or a normal scenario.
  • In the pessimistic scenario, it could be assumed that there will be a drastic change in the size of the animal antimicrobials and antibiotics market. The outbreak of COVID-19 originated from a meat market in Wuhan (China), which has negatively affected the consumption of food products derived from animal sources. This can be attributed to the occurrence of various diseases, such as swine flu, Zika virus, Hantavirus, and the ongoing bird flu, among others, which have originated from livestock. Additionally, antimicrobial stewardship efforts from major companies may be undermined because of high workloads and shifting priorities related to COVID-19. Thus, this is expected to have a negative effect on the consumption of animal-sourced products. Furthermore, trade barriers in various regions and the adoption of alternative sources, such as plant-based ingredients, are also expected to restrain the growth of the market.
  • In the realistic scenario, it could be assumed that there will be a partial effect of COVID-19 on the animal antimicrobials and antibiotics market. In this scenario, limited access to current and potential customers has significantly reduced market players’ ability to sell new antimicrobial susceptibility testing systems and to implement previously sold systems, thereby reducing the growth in the production of antimicrobials and antibiotics. Additionally, considerable losses in the gross domestic product (GDP) are also projected in low- and middle-income countries (LMICs) due to AMR by the year 2050, which is further going to be reduced due to economic slowdowns in the post-COVID period. Antimicrobial Resistance (AMR) is a serious and growing global public health threat. The post-COVID scenario is expected to be impacted by a rise in AMR in humans and animals due to more stress on antibiotic-dependent healthcare systems to combat secondary bacterial infections. Factors such as interruptions in antibiotic stewardship programs in hospitals and communities, prescription of antibiotics for COVID patients misdiagnosed with bacterial bronchitis, over-prescription in telehealth consultations, and easy accessibility of medicines from online pharmacies were associated with AMR. This is expected to have a negative effect on consumers toward animal-sourced products.

Animal Antimicrobials and Antibiotics Market Dynamics

Drivers Rising demand for animal-derived food products

Animal-derived food products include beef, veal, buffalo meat, lamb and goat meat, pork, poultry meat, milk and dairy products, and eggs. The livestock sector is highly dynamic and was valued at USD 6.8 trillion in 2018. Livestock products contribute 33% to protein consumption globally; however, this figure varies across developed and developing countries. The overall livestock sector is expected to witness significant growth due to the high consumption of animal-derived food products. An FAO (Food and Agriculture Organization of the United Nations) survey in 2018 on mapping the supply and demand for animal-sourced food estimates that Asian countries will register the highest growth in the demand for livestock products such as beef, milk, mutton, pork, and poultry products (chicken and eggs). According to the Guardian and Bureau of Investigative Journalism, the number of industrial-sized pig and poultry units in the UK has risen by 7% from 1,669 in 2017 to 1,786 in 2020, owing to the growth of this market.

According to the FAO, South Asia is one of the major regions for dairy production and accounted for 20–25% of the global milk production in 2019. In this region, India was the largest producer and consumer of milk, followed by China and Pakistan. In 2020, the consumption of meat in India was over 3.9 million metric tons; by 2030, this is expected to increase to 145.7 million metric tons.

China accounted for the largest share of the total pork, beef, and poultry meat consumption in the Asia Pacific in 2019. The overall consumption of animal-derived food products is projected to increase by 2030. To maintain the quality of animal-derived food products and reduce the risk of zoonotic disease transmittance, livestock producers and the meat & milk industries are increasingly utilizing animal health products. In addition, in sub-Saharan Africa and South Asia, the consumption of livestock products is expected to increase from 200 kcal per person per day in 2000 to around 400 kcal per person per day by 2050. According to the North American Meat Institute, the meat and poultry industry is the largest segment in the US agriculture sector. US meat production totaled 52 billion pounds in 2017, and US poultry production totaled 48 billion pounds in 2017. With the growing consumption of animal-derived food products, the use of antimicrobials and antibiotics is expected to increase to maintain animal health.

Restrains Growing resistance to antimicrobials and antibiotics

Intensive usage of antimicrobials in the management of animal diseases leads to resistance among microorganisms. According to the latest report published by nature.com, it is now estimated that antimicrobial resistance (AMR) among bacteria and viruses leads to 700,000 human deaths annually, posing a significant public health challenge worldwide. The resistant clones of bacteria are found globally. with over 90% being resistant to commonly used antibiotics such as co-trimoxazole, penicillin, ampicillin, and gentamicin, among others. Most human diseases originate from animals, with 61% being zoonotic. Animal diseases caused by microorganisms can be controlled by vaccination, good hygiene, and the use of antibiotics and antimicrobials.

Antibiotic and antimicrobial resistance is a burning issue in the animal health market. To tackle this issue, most farmers and pet owners tend to increase the dosage of antibiotics and antimicrobials or change the antibiotics and antimicrobials used. However, these practices may prove detrimental in the long run and result in multi-drug-resistant microorganism species. According to a European Consumer Organization report, in six EU countries, more than 70% of all meat products tested were contaminated with antibiotic-resistant bacteria. In 2017, the WHO suggested reducing antibiotic use in animals used in the food industry. Due to the increased risk of antibiotic-resistant bacteria, the WHO strongly suggested restrictions on antibiotics being used for growth promotion and antibiotics used on healthy animals. Animals that require antibiotics should be treated with antibiotics that pose the smallest risk to human health.

Antibiotic-resistant bacteria in livestock are a major concern. Food-producing animals serve as a reservoir of resistant pathogens that can be transmitted from animals to humans via direct contact between animals and humans or through the food chain and the environment. Antimicrobial-resistant infections in humans can cause longer illnesses, increased frequency of hospitalizations, and treatment failures resulting in death. According to the WHO, over 400,000 people die each year from foodborne diseases, with over one-third of these deaths occurring in children under five years of age. The vast majority of foodborne illnesses are caused by microbes, including bacteria. Some bacteria have become resistant to more than one type of antibiotic, making it more difficult to treat the infections they cause. Veterinarians, therefore, recommend the use of less-concentrated antibiotics to treat animals. Such practices have the potential to significantly affect the consumption of antibiotics across the globe.

Opportunities: Growth in the companion animal population

The adoption of companion animals has been associated with positive health benefits, such as reduced cardiac arrhythmias, normalization of blood pressure, decreased anxiety, greater psychological stability, and improved wellbeing. These benefits have driven the number of pet owners globally over the years. According to the APPA National Pet Owners Survey 2018–19, the dog population in the US increased from 77.8 million in 2014 to 89.4 million in 2017, while the cat population increased from 85.8 million in 2014 to 95.6 million in 2017. A similar trend is observed in many European countries. According to the European Pet Food Industry Federation (FEDIAF), the dog population in Germany increased from 6.84 million in 2014 to 10.1 million in 2019, whereas the cat population in the country increased from 11.80 million in 2014 to 14.7 million in 2019. Emerging markets such as Brazil, China, India, and Mexico are also witnessing higher animal ownership rates than five years ago. According to the India International Pet Trade Fair (IIPTF), the number of pets in the country increased from 11 million in 2014 to 19.5 million in 2018. Similarly, according to the Royal Society for the Prevention of Cruelty to Animals (RSPCA), Australia has one of the highest pet ownership rates in the world. There are over 29 million pets on the island continent. Approximately 61% of households in Australia own pets, with dogs being the most common (40%), followed by cats (27%). In India, around 600,000 pets are adopted every year, according to the India International Pet Trade Fair. The growth in companion animal ownership and willingness to spend on the health and welfare of companion animals are expected to support the growth of the animal health industry, which, in turn, will drive growth in dependent industries, such as animal antimicrobials and antibiotics.

Challenges Stringent approval process for antimicrobials and antibiotics

Antibiotics and antimicrobials are intended to improve the health of livestock and companion animals and increase the productivity of food-producing animals. To ensure that these products do not exhibit negative effects on animal health and ensure their quality and efficacy, various authorities have set stringent regulations to approve animal pharmaceutical products.

The US FDA; Canadian Food Agency; European Medical Agency; Ministry of Agriculture, Forestry, and Fisheries (MAFF); and Australian Pesticides and Veterinary Medicines Authority (APVMA) are some of the major regulatory bodies that approve medicines used for veterinary purposes. The Veterinary International Committee for Harmonization (VICH) also plays a significant role in bringing together regulatory authorities in the US, Europe, and Japan; it also harmonizes guidelines and technical requirements to register veterinary products.

These regulatory bodies have set stringent regulations to approve veterinary pharmaceutical products. Regulatory standards for the approval of new veterinary pharmaceutical products, including antimicrobials, antibiotics, vaccines, parasiticides, and other pharmaceutical products, are also very stringent in countries such as Australia, Japan, and China.
Typically, the approval of veterinary pharmaceuticals in the US and European markets may take up to 5 to 11 years and incur expenditures of USD 75–100 million (from product development to commercialization). Considering the time-consuming and expensive nature of the development and approval process of new veterinary pharmaceutical products, many market players are reluctant to invest in developing antimicrobials and antibiotics for emerging microorganisms and parasites.

The Tetracyclines segment accounted for the largest market share in 2020.

Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products. In 2020, the tetracyclines segment accounted for 48.9% of the global animal antimicrobials and antibiotics market. Tetracyclines exhibit advantages such as the highest potency against pathogenic microorganisms, are well-absorbed, show low toxicity, and are relatively inexpensive compared to other animal antimicrobial and antibiotic products. These advantages contribute to the large share of this product segment. The fluoroquinolones segment is expected to grow at the highest CAGR of 8.0% during the forecast period. Advantages such as higher efficacy at low concentrations, quick penetration through tissues, and the availability of variations in the route of administration result in the higher adoption of fluoroquinolones among end users.

The Premixes segment accounted for the largest market share in 2020.

Based on the mode of delivery, the global animal antimicrobials and antibiotics market is segmented into premixes, oral powders, oral solutions, injections, and other modes of delivery. In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antimicrobials and antibiotics market. The large share of this segment can be attributed to the advantages of premixes, such as simplified mode of administration and lower instability and hygroscopicity of formulations. The injections segment is expected to witness the highest CAGR of 4.9% during the forecast period. Advantages such as immediate delivery of drugs and rapid onset of drug effects are expected to drive growth in this market.

The food producing animal segment accounted for the largest market share in 2020.

Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals. In 2020, the food-producing animals segment accounted for the largest share of around 73.4%. This segment is also expected to register the highest CAGR of 3.9% during the forecast period. The large share of this segment is mainly due to the rising demand for animal-derived food products, increase in animal healthcare expenditure, and greater concerns about zoonotic diseases.

Asia Pacific recorded the highest CAGR for animal antimicrobials and antibiotics market in 2019

The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 30.3% of the global animal antimicrobials and antibiotics market. The large share of this region is mainly due to the increase in the region’s animal population, rising demand for animal-derived food products, growth in pet insurance, and rising animal health expenditure compared to other regions.

The Asia Pacific region is projected to grow at the highest CAGR of 5.4% during the forecast period. Factors such as the rapidly increasing animal population and rising demand for animal-derived food products are driving the growth of this market in the APAC.

Animal Antibiotics and Antimicrobials Market  by Region

Key Market Players

Some of the prominent players in the animal antimicrobials and antibiotics market are Boehringer Ingelheim (Germany), Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc (US), Phibro Animal Health (US), Virbac (France), Vetoquinol S.A. (France), Ceva Santé Animale (France), Dechra Pharmaceuticals Plc (UK), Kyoritsu Seiyaku (Japan), Tianjin Ringpu (China), HIPRA (Spain), Zydus Animal Health (US), China Animal Husbandry (China), and Inovet (Belgium).

Scope of the report

Report Metric

Details

Market size available for years

2019-2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

By Type of product, Mode of Delivery, Animal Type and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies covered

The major market players include Boehringer Ingelheim (Germany), Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc. (US), Phibro Animal Health (US), Virbac (France), Vetoquinol SA (France), HIPRA (Spain), Ceva Santé Animale (France), Dechra Pharmaceuticals Plc (UK), Kyoritsu Seiyaku (Japan), Tianjin Ringpu (China), China Animal Husbandry (China), Endovac Animal Health (US), Zydus (India), Indian Immunologicals Pvt. Ltd. (India), UCBVET (US), American Reagent Inc. (US), Neogen Corporation (US), Huvepharma Inc. (US), Ayurvet (India), Ashish Life Science (India), Inovet (Belgium), Lutim Pharma (India), and ECO Animal Health (US).

The study categorizes the animal antimicrobials and antibiotics market based on By Type of Product, Mode of Delivery, and Animal Type at the regional and global level.

By Type of Product

  • Tetracyclines
  • Penicillins
  • Sulfonamides
  • Macrolides
  • Aminoglycosides
  • Lincosamides
  • Fluoroquinolones
  • Cephalosporins
  • Other Antimicrobials and Antibiotics

By Mode of Delivery

  • Premixes
  • Oral Powder
  • Oral Solution
  • Injection
  • Others

By Animal Type

  • Food-Producing Animals
    • Cattle
    • Pigs
    • Poultry
    • Sheep and Goats
    • Other Food-producing Animals
  • Companion Animals
    • Dogs
    • Cats
    • Horses
    • Other Companion Animals

Recent Developments

  • In 2020, Zoetis (US) acquired entered into an agreement with Trianni Inc. (US) to develop transgenic monoclonal antibody platforms for the discovery of new veterinary treatmentsThe acquisition of
  • In  2020, Zoetis (US)  received FDA approval for Marboquin
  • In 2019, Elanco (US) collaborated with AgBiome to develop nutritional health products for porcine animals.
  • In 2019, Elanco Animal Health  (US) Announced the acquisition of Bayer’s Animal Health Business, thereby expanding its own companion animal business and portfolio mix by creating a balance between its food animal and companion animal segments
  • In 2019,  Boehringer Ingelheim (Germany) acquired Sanofi’s Animal Health business (Merial), and Sanofi took over Boehringer Ingelheim’s Consumer Healthcare (CHC) business. The acquisition of Merial made BI the world’s second-largest animal health company

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 32)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
           TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
           FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
           FIGURE 6 COUNTRY-LEVEL ANALYSIS OF THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET
           FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 8 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 9 MARKET DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 48)
           FIGURE 10 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
           FIGURE 11 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2021 VS. 2026 (USD MILLION)
           FIGURE 12 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY ANIMAL TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET OVERVIEW
           FIGURE 14 RISING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS AND GROWING INCIDENCE OF ZOONOTIC DISEASES TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY AND COUNTRY (2020)
           FIGURE 15 CHINA ACCOUNTED FOR THE LARGEST SHARE OF THE APAC ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET IN 2020
    4.3 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 16 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
    4.4 REGIONAL MIX: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET (2021−2026)
           FIGURE 17 NORTH AMERICA WILL CONTINUE TO DOMINATE THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET IN 2026
    4.5 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           TABLE 2 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising demand for animal-derived food products
           TABLE 3 PAST AND PROJECTED TRENDS IN THE CONSUMPTION OF MEAT AND MILK IN DEVELOPED AND DEVELOPING REGIONS
           FIGURE 19 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
           FIGURE 20 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
           FIGURE 21 ASIA WAS THE HIGHEST CONSUMER OF MEAT AND MILK IN THE WORLD IN 2018
                    5.2.1.2 Increasing incidence of zoonotic diseases
           TABLE 4 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2009–2019)
                    5.2.1.3 Increasing investments from private players
                    5.2.1.4 Rising demand for pet insurance and growing animal health expenditure
           FIGURE 22 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2014 VS. 2019 (USD MILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 Limited number of new antibiotics
                    5.2.2.2 Growing resistance to antimicrobials and antibiotics
                    5.2.2.3 Routine prophylactic use of antibiotics being replaced by good husbandry, probiotics, and hygiene practices
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Untapped emerging markets
                    5.2.3.2 Growth in the companion animal population
           TABLE 5 US: COMPANION ANIMAL POPULATION (2010–2025)
           TABLE 6 UK : COMPANION ANIMAL POPULATION (2010–2025)
           TABLE 7 INDIA : COMPANION ANIMAL POPULATION IN (2010–2025)
           TABLE 8 SAUDI ARABIA: COMPANION ANIMAL POPULATION (2010–2025)
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent approval process for antimicrobials and antibiotics

6 INDUSTRY INSIGHTS (Page No. - 66)
    6.1 INTRODUCTION
    6.2 COVID-19 IMPACT ANALYSIS
           6.2.1 IMPACT OF COVID-19 ON THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET
    6.3 INDUSTRY TRENDS
           FIGURE 23 GROWING CONSOLIDATION IN THE ANIMAL HEALTH INDUSTRY IS A MAJOR TREND IN THE ANIMAL ANTIMICROBIALS & ANTIBIOTICS MARKET
           6.3.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTH INDUSTRY
           TABLE 9 SOME MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY (2017–2019)
           6.3.2 GROWING FOCUS ON LIMITING THE USE OF ANTIBIOTICS IN LIVESTOCK ANIMALS
           6.3.3 HIGH GROWTH IN EMERGING MARKETS
    6.4 REGULATORY ANALYSIS
           FIGURE 24 DEVELOPMENT AND APPROVAL PROCESS FOR ANIMAL PHARMACEUTICAL PRODUCTS
    6.5 VALUE CHAIN ANALYSIS
           FIGURE 25 ANIMAL ANTIMICROBIALS AND ANTIBODY MARKET: VALUE CHAIN ANALYSIS
    6.6 ECOSYSTEM MARKET MAP
           TABLE 10 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: ECOSYSTEM MAPPING
           FIGURE 26 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: ECOSYSTEM MARKET MAP
    6.7 PORTER’S FIVE FORCES ANALYSIS
           TABLE 11 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           6.7.1 THREAT FROM NEW ENTRANTS
           6.7.2 THREAT FROM SUBSTITUTES
           6.7.3 BARGAINING POWER OF SUPPLIERS
           6.7.4 BARGAINING POWER OF BUYERS
           6.7.5 INTENSITY OF COMPETITIVE RIVALRY
    6.8 SUPPLY CHAIN ANALYSIS
           FIGURE 27 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: SUPPLY CHAIN ANALYSIS
    6.9 PATENT ANALYSIS
           TABLE 12 LIST OF ANTIBIOTICS AND THEIR PATENT YEARS
    6.10 PRICING ANALYSIS

7 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT (Page No. - 82)
    7.1 INTRODUCTION
           FIGURE 28 SALES OF ANTIMICROBIAL AGENTS, BY ANTIMICROBIAL CLASS, AS A PERCENTAGE OF THE TOTAL SALES FOR FOOD-PRODUCING SPECIES (IN MG/PCU): AGGREGATED BY 31 EUROPEAN COUNTRIES, 2018
           TABLE 13 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 14 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.2 TETRACYCLINES
           7.2.1 REDUCED COST OF TETRACYCLINES IS A KEY FACTOR DRIVING MARKET GROWTH ACROSS THE GLOBE
           TABLE 15 TETRACYCLINES OFFERED BY KEY MARKET PLAYERS
           FIGURE 29 SALES OF TETRACYCLINES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 16 TETRACYCLINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 PENICILLINS
           7.3.1 RISING INCIDENCE OF ZOONOTIC DISEASES IN LIVESTOCK ANIMALS TO DRIVE THE DEMAND FOR PENICILLINS
           TABLE 17 PENICILLINS OFFERED BY KEY MARKET PLAYERS
           FIGURE 30 SALES OF PENICILLINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 18 PENICILLINS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 SULFONAMIDES
           7.4.1 REDUCED COST AND MULTIPLE APPLICATIONS IN LIVESTOCK INFECTIONS TO DRIVE THE DEMAND FOR SULFONAMIDES IN RURAL REGIONS
           TABLE 19 SULFONAMIDES OFFERED BY KEY MARKET PLAYERS
           FIGURE 31 SALES OF SULFONAMIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 20 SULFONAMIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 MACROLIDES
           7.5.1 INCREASING PRODUCTION OF CATTLE-DERIVED FOOD PRODUCTS TO BOOST THE DEMAND FOR MACROLIDES
           TABLE 21 MACROLIDES OFFERED BY KEY MARKET PLAYERS
           FIGURE 32 SALES OF MACROLIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 22 MACROLIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 AMINOGLYCOSIDES
           7.6.1 AMINOGLYCOSIDES ARE COMMONLY USED TO CONTROL LOCAL AND SYSTEMIC INFECTIONS CAUSED BY SUSCEPTIBLE AEROBIC BACTERIA (GENERALLY GRAM-NEGATIVE)
           TABLE 23 AMINOGLYCOSIDES OFFERED BY KEY MARKET PLAYERS
           FIGURE 33 SALES OF AMINOGLYCOSIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 24 AMINOGLYCOSIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.7 LINCOSAMIDES
           7.7.1 LINCOSAMIDES EXHIBIT SERIOUS SIDE EFFECTS—A KEY FACTOR LIMITING MARKET GROWTH
           TABLE 25 LINCOSAMIDES OFFERED BY KEY MARKET PLAYERS
           FIGURE 34 SALES OF LINCOSAMIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 26 LINCOSAMIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.8 FLUOROQUINOLONES
           7.8.1 AVAILABILITY OF VARIATIONS IN THE ROUTE OF ADMINISTRATION RESULTS IN THE HIGHER ADOPTION OF FLUOROQUINOLONES AMONG END USERS
           TABLE 27 FLUOROQUINOLONES OFFERED BY KEY MARKET PLAYERS
           FIGURE 35 SALES OF FLUOROQUINOLONES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 28 FLUOROQUINOLONES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.9 CEPHALOSPORINS
           7.9.1 CEPHALOSPORINS ARE ACTIVE AGAINST A WIDE RANGE OF BACTERIA—A KEY FACTOR DRIVING MARKET GROWTH
           TABLE 29 PROPERTIES OF SEVERAL GENERATIONS OF CEPHALOSPORINS
           TABLE 30 CEPHALOSPORINS OFFERED BY KEY MARKET PLAYERS
           FIGURE 36 SALES OF FIRST- AND SECOND-GENERATION CEPHALOSPORINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           FIGURE 37 SALES OF THIRD- AND FOURTH-GENERATION CEPHALOSPORINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 31 CEPHALOSPORINS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.10 OTHER ANTIMICROBIALS AND ANTIBIOTICS
           FIGURE 38 SALES OF POLYMYXINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU)
           TABLE 32 OTHER ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY (Page No. - 104)
    8.1 INTRODUCTION
           TABLE 33 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
    8.2 PREMIXES
           8.2.1 ADVANTAGES OF PREMIXES, SUCH AS SIMPLIFIED MODE OF ADMINISTRATION AND LOWER INSTABILITY AND HYGROSCOPICITY, TO DRIVE MARKET GROWTH
           TABLE 34 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR PREMIXES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 ORAL SOLUTIONS
           8.3.1 ORAL SOLUTIONS PRODUCE SYSTEMIC EFFECTS BUT SHOW A RELATIVELY SLOW ONSET OF ACTION
           TABLE 35 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR ORAL SOLUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 ORAL POWDERS

           TABLE 36 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR ORAL POWDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 INJECTIONS
           8.5.1 INJECTABLE DRUGS PROVIDE SYSTEMIC EFFECTS AND POSSESS GREATER BIOAVAILABILITY, OFFERING A FASTER ONSET OF ACTION
           TABLE 37 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR INJECTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 OTHER MODES OF DELIVERY
           TABLE 38 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR OTHER MODES OF DELIVERY, BY COUNTRY, 2019–2026 (USD MILLION)

9 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL (Page No. - 112)
    9.1 INTRODUCTION
           TABLE 39 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
    9.2 FOOD-PRODUCING ANIMALS
           TABLE 40 GLOBAL POPULATION OF FOOD-PRODUCING ANIMALS, 1970–2030 (MILLION)
           TABLE 41 PER CAPITA CONSUMPTION OF MEAT IN MAJOR APAC COUNTRIES, 2019 (IN KG)
           TABLE 42 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 43 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.1 CATTLE
                    9.2.1.1 Increasing beef consumption and milk production to drive growth in this market segment
           TABLE 44 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR CATTLE, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.2 PIGS
                    9.2.2.1 Growing incidence of zoonotic diseases will require better health maintenance of pigs—a key factor driving market growth
           TABLE 45 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR PIGS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.3 POULTRY
                    9.2.3.1 Growing egg consumption in emerging countries to drive market growth
           FIGURE 39 LEADING EGG PRODUCING COUNTRIES, 2018 (NUMBER OF EGGS, IN BILLION)
           TABLE 46 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR POULTRY, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.4 SHEEP AND GOATS
                    9.2.4.1 Increasing population of sheep and goats to drive growth in this segment
           TABLE 47 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR SHEEP AND GOATS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.2.5 OTHER FOOD-PRODUCING ANIMALS
           FIGURE 40 PER CAPITA FISH CONSUMPTION, 2019 VS. 2029
           TABLE 48 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR OTHER FOOD-PRODUCING ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 COMPANION ANIMALS
           TABLE 49 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 50 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.3.1 DOGS
                    9.3.1.1 Growing adoption of dogs to drive growth in this market segment
           FIGURE 41 GROWING POPULATION OF PET DOGS IN INDIA (MILLION)
           FIGURE 42 POPULATION OF PET DOGS GLOBALLY (MILLION)
           TABLE 51 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR DOGS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.3.2 CATS
                    9.3.2.1 Growing research on feline health and wellbeing to support the market growth
           TABLE 52 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR CATS, BY COUNTRY, 2019–2026 (USD MILLION)
           9.3.3 HORSES
                    9.3.3.1 Declining horse population necessitates the adoption of health products—a key factor driving market growth
           TABLE 53 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR HORSES, BY COUNTRY, 2019–2026 (USD MILLION)
           9.3.4 OTHER COMPANION ANIMALS
           TABLE 54 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION)

10 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY REGION (Page No. - 130)
     10.1 INTRODUCTION
           TABLE 55 COMPANION ANIMAL AND FOOD-PRODUCING ANIMAL POPULATION, BY COUNTRY, 2020 (IN THOUSAND)
           TABLE 56 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
           FIGURE 43 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA
           FIGURE 44 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET SNAPSHOT
           TABLE 57 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 58 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 59 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 60 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 61 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 62 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Rising pet expenditure and increasing meat consumption are driving the market in the US
           FIGURE 45 US: GROWTH IN BEEF CONSUMPTION, 2014–2019 (BILLION POUNDS)
           FIGURE 46 US: INCREASE IN PET EXPENDITURE, 2010–2019 (USD BILLION)
           FIGURE 47 DOMESTIC SALES AND DISTRIBUTION OF MEDICALLY IMPORTANT ANTIMICROBIAL DRUGS FOR PRODUCTION AND THERAPEUTIC INDICATIONS IN THE US (THOUSAND KG)
           TABLE 63 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018
           TABLE 64 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 65 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 66 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 67 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 68 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Growing pet adoption rate to drive the market in Canada
           TABLE 69 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 70 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 71 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 72 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 73 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
     10.3 EUROPE
           TABLE 74 EUROPE: LIVESTOCK POPULATION, BY ANIMAL, 2011–2018 (MILLION HEAD)
           TABLE 75 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 76 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 77 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 78 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 79 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 80 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.3.1 SPAIN
                        10.3.1.1 Large volume of sales of important antibiotics in this country to drive market growth
           TABLE 81 SPAIN: LARGE ANIMAL POPULATION, 2001–2019 (MILLION)
           TABLE 82 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 83 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 84 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 85 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 86 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.3.2 ITALY
                        10.3.2.1 Need to curb zoonotic diseases in livestock will contribute to the demand for animal antimicrobials and antibiotics market in Italy
           TABLE 87 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 88 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 89 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 90 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 91 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.3.3 GERMANY
                        10.3.3.1 Increasing number of pets, increasing veterinary visits, and growing healthcare expenditure to boost the growth of the animal antimicrobials and antibiotics market in Germany
           TABLE 92 GERMANY: COMPANION ANIMAL POPULATION, 2012–2018 (MILLION)
           FIGURE 48 SALES SURVEILLANCE OF ANTIMICROBIALS FOR VETERINARY USE IN GERMANY (2011 TO 2018)
           TABLE 93 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 94 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 95 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 96 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 97 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Presence of major players has ensured the strong share of France in the overall market
           TABLE 98 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 99 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 100 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 101 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 102 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.3.5 UK
                        10.3.5.1 Increasing pet ownership is expected to drive market growth
           FIGURE 49 SALES OF ANTIBIOTICS FOR FOOD-PRODUCING ANIMALS IN THE UK FROM 2015 TO 2019 (MG/KG)
           TABLE 103 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 104 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 105 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 106 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 107 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
           TABLE 108 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 109 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 110 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 111 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 112 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC (APAC)
           TABLE 113 ASIA PACIFIC: FOOD-PRODUCING ANIMAL POPULATION, 2010–2017 (MILLION)
           FIGURE 50 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET SNAPSHOT
           TABLE 114 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 115 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 116 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 117 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 118 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 119 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 China dominates the APAC animal antimicrobials and antibiotics market
           TABLE 120 CHINA: FOOD-PRODUCING ANIMAL POPULATION, 2012–2019 (MILLION)
           TABLE 121 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 122 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 123 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 124 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 125 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Rising demand for imported breeds is driving pet adoption in the country
           TABLE 126 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN JAPAN (2000 VS. 2030) (THOUSAND METRIC TONS)
           FIGURE 51 VOLUMES OF VETERINARY ANTIMICROBIALS SOLD BY PHARMACEUTICAL COMPANIES IN JAPAN, 2001–2017 (IN TONS OF ACTIVE INGREDIENT)
           FIGURE 52 AMOUNT OF ANTIMICROBIAL FEED ADDITIVES MANUFACTURED IN JAPAN, 2003–2017 (IN TONS OF ACTIVE INGREDIENT)
           TABLE 127 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 128 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 129 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 130 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 131 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising food-producing animal population and growing awareness about animal health will contribute to market growth during the forecast period
           TABLE 132 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN INDIA (2000 VS. 2030) (THOUSAND METRIC TONS)
           TABLE 133 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 134 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 135 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 136 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 137 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC (REST OF APAC)
           TABLE 138 REGULATORY SCENARIO FOR ANTIBIOTICS IN THE ROAPAC, BY COUNTRY
           TABLE 139 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 140 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 141 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 142 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 143 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
           TABLE 144 LATIN AMERICA: FOOD-PRODUCING ANIMALS POPULATION, BY COUNTRY (2010–2014) (MILLION)
           TABLE 145 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 146 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 147 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 148 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 149 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
           TABLE 150 AFRICA: NUMBER OF VETERINARIANS, 2010 VS. 2014 VS. 2016
           TABLE 151 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 152 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION)
           TABLE 153 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION)
           TABLE 154 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 155 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 187)
     11.1 INTRODUCTION
           FIGURE 53 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN 2017 AND JAN 2021
     11.2 MARKET EVALUATION FRAMEWORK
           FIGURE 54 MARKET EVALUATION FRAMEWORK: ACQUISITIONS—THE MOST WIDELY ADOPTED STRATEGY
     11.3 PRODUCT PORTFOLIO MATRIX
           TABLE 156 PLAYERS IN THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: PRODUCT PORTFOLIO ANALYSIS
     11.4 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: GEOGRAPHICAL ASSESSMENT
           FIGURE 55 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET (2019)
     11.5 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: R&D EXPENDITURE
           FIGURE 56 R&D EXPENDITURE OF KEY PLAYERS IN THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET (2019)
     11.6 REVENUE ANALYSIS: TOP 5 PLAYERS
           FIGURE 57 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: REVENUE ANALYSIS (2019)
     11.7 VENDOR DIVE
             11.7.1 STARS
             11.7.2 EMERGING LEADERS
             11.7.3 PERVASIVE PLAYERS
             11.7.4 EMERGING COMPANIES
           FIGURE 58 COMPETITIVE LEADERSHIP MAPPING: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, 2020
     11.8 MARKET SHARE ANALYSIS
           TABLE 157 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: DEGREE OF COMPETITION
           FIGURE 59 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     11.9 COMPETITIVE SITUATION AND TRENDS
             11.9.1 PRODUCT LAUNCHES & APPROVALS
           TABLE 158 PRODUCT LAUNCHES & APPROVALS
             11.9.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
           TABLE 159 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
             11.9.3 MERGERS, ACQUISITIONS, AND DIVESTITURES
           TABLE 160 MERGERS, ACQUISITIONS, AND DIVESTITURES
             11.9.4 EXPANSIONS
           TABLE 161 EXPANSIONS
     11.10 SME MATRIX
             11.10.1 COMPETITIVE LEADERSHIP MAPPING (SMES)
                        11.10.1.1 Progressive companies
                        11.10.1.2 Starting blocks
                        11.10.1.3 Responsive companies
                        11.10.1.4 Dynamic companies
           FIGURE 60 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SME, 2020

12 COMPETITIVE EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 201)
     12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MNM view)* 
             12.1.1 ZOETIS, INC.
           TABLE 162 ZOETIS, INC.: BUSINESS OVERVIEW
           FIGURE 61 ZOETIS: COMPANY SNAPSHOT (2019)
             12.1.2 MERCK & CO., INC.
           TABLE 163 MERCK AND CO., INC: BUSINESS OVERVIEW
           FIGURE 62 MERCK & CO., INC.: COMPANY SNAPSHOT (2019)
             12.1.3 BOEHRINGER INGELHEIM GMBH
           TABLE 164 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW
           FIGURE 63 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019)
             12.1.4 ELANCO ANIMAL HEALTH
           TABLE 165 ELANCO ANIMAL HEALTH: BUSINESS OVERVIEW
           FIGURE 64 ELANCO ANIMAL HEALTH: COMPANY SNAPSHOT (2019)
             12.1.5 CEVA SANTÉ ANIMALE
           TABLE 166 CEVA SANTÉ ANIMALE: BUSINESS OVERVIEW
             12.1.6 VIRBAC
           TABLE 167 VIRBAC: BUSINESS OVERVIEW
           FIGURE 65 VIRBAC: COMPANY SNAPSHOT (2019)
             12.1.7 VETOQUINOL SA.
           TABLE 168 VETOQUINOL S.A.: BUSINESS OVERVIEW
           FIGURE 66 VETOQUINOL SA: COMPANY SNAPSHOT (2019)
             12.1.8 DECHRA PHARMACEUTICALS PLC
           TABLE 169 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
           FIGURE 67 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019)
             12.1.9 PHIBRO ANIMAL HEALTH
           TABLE 170 PHIBRO ANIMAL HEALTH: BUSINESS OVERVIEW
           FIGURE 68 PHIBRO ANIMAL HEALTH: COMPANY SNAPSHOT (2019)
             12.1.10 KYORITSU SEIYAKU
           TABLE 171 KYORITSU SEIYAKU: BUSINESS OVERVIEW
             12.1.11 ZYDUS ANIMAL HEALTH
           TABLE 172 ZYDUS ANIMAL HEALTH: BUSINESS OVERVIEW
           FIGURE 69 ZYDUS: COMPANY SNAPSHOT (2019)
             12.1.12 TIANJIN RINGPU
           TABLE 173 TIANJIN RINGPU: BUSINESS OVERVIEW
             12.1.13 HIPRA
           TABLE 174 HIPRA: BUSINESS OVERVIEW
             12.1.14 CHINA ANIMAL HUSBANDRY
           TABLE 175 CHINA ANIMAL HUSBANDRY: BUSINESS OVERVIEW
             12.1.15 INOVET
           TABLE 176 INOVET: BUSINESS OVERVIEW
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies. 
     12.2 OTHER EMERGING COMPANIES
             12.2.1 ENDOVAC ANIMAL HEALTH
             12.2.2 ECO ANIMAL HEALTH GROUP PLC
             12.2.3 INDIAN IMMUNOLOGICALS LTD.
             12.2.4 ASHISH LIFE SCIENCE (ALS)
             12.2.5 LUTIM PHARMA

13 APPENDIX (Page No. - 247)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

 

This study involved four major activities for estimating the current size of the animal antimicrobials and antibiotics market. Exhaustive secondary research was conducted to collect information on the market as well as its peer and parent markets. The next step focused on validating these findings, assumptions, and sizing with industry experts across the value chain through primary research. Revenue Share Analysis, Parent Market and top-down approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the sizes of segments and sub-segments.

Secondary Research

In the secondary research process, various secondary sources such as D&B Hoovers, Bloomberg Business, and Factiva have been referred to identify and collect information for this study. These secondary sources include annual reports, press releases and investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard and silver-standard websites, regulatory bodies, and databases.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies operating in the animal antimicrobials and antibiotics market. Primary sources from the demand side include experts from hospitals and veterinary clinics and research centers. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on the key industry trends and key market dynamics, such as market drivers, restraints, challenges, and opportunities.

Animal Antibiotics and Antimicrobials Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the animal antimicrobials and antibiotics market was arrived at after data triangulation from two different approaches, as mentioned below.

Approach to calculate the revenue of different players in the animal antimicrobials and antibiotics market

The size of the animal antimicrobials and antibiotics market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global animal antimicrobials and antibiotics market was derived.

Approach to derive the market size and estimate market growth

The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Data Triangulation

After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Objectives of the Study

  • To define, describe, and forecast the global animal antimicrobials and antibiotics market on the basis of product, mode of delivery, animal type, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa, along with the major countries in these regions
  • To profile the key players and comprehensively analyze their market shares and core competencies2 in the animal antimicrobials and antibiotics market
  • To track and analyze competitive developments such as partnerships, collaborations, acquisitions, divestures, product development activities, and R&D activities in the animal antimicrobials and antibiotics market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top companies

Geographic Analysis

  • Further breakdown of the RoAPAC market into South Korea, New Zealand, Australia, Singapore, and other countries
  • Further breakdown of the RoE market into Russia, the Netherlands, Switzerland, and other countries

Company Information

  • Detailed analysis and profiling of additional market players (Up to five)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Animal Antibiotics and Antimicrobials Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Animal Antibiotics and Antimicrobials Market

Request For Special Pricing
Report Code
PH 2458
Published ON
Mar, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Animal Antibiotics and Antimicrobials Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved